A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2
U
Utpal Dave, MD
Primary Investigator
Enrolling By Invitation
18-100 years
All
Phase
1/2
2 Locations
Brief description of study
A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: cancer,relapse peripheral T-cell lymphoma
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 11582
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
